Trial Profile

Phase I trial of AS-0871 for the treatment of autoimmune diseases

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AS 0871 (Primary)
Indications Autoimmune disorders
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Carna Biosciences

Most Recent Events

25 Aug 2020 According to a Carna Biosciences media release, preliminary results are expected in the first half of 2021.
25 Aug 2020 According to a Carna Biosciences media release, the Central Committee on Research Involving Human Subjects (CCMO) and the Ethics Committee approved a Clinical Trial Application (CTA) for AS-0871 in February 2020, but this study initially planned in the first quarter was rescheduled due to the COVID-19 pandemic in Europe.
25 Aug 2020 According to a Carna Biosciences media release, first patient was dosed in this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com